Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab-Reference-Cited by-同舟云学术

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

Published:2019-08 Issue: Volume:33 Page:82-87
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Dekker I.^ORCID,Leurs C.E.^ORCID,Hagens M.H.J.,van Kempen Z.L.E.,Kleerekooper I.,Lissenberg-Witte B.I.,Barkhof F.,Uitdehaag B.M.J.,Balk L.J.,Wattjes M.P.,Killestein J.

Funder

Dutch MS Research Foundation

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference30 articles.

1. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis;Belachew;Eur. J. Neurol.,2011

2. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results;Butzkueven;J. Neurol. Neurosurg. Psychiatry,2014

3. Multiple sclerosis;Compston;Lancet,2008

4. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study;Havrdova;Lancet Neurol.,2009

5. Freedom from disease activity in multiple sclerosis;Havrdova;Neurology,2010

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis;Multiple Sclerosis Journal;2024-01-18

2. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS);Journal of Neurology, Neurosurgery & Psychiatry;2023-11-14

3. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light;Multiple Sclerosis Journal;2023-08-02

4. Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up;Multiple Sclerosis and Related Disorders;2023-06

5. Multiple Sclerosis and Depression: Translation and Adaptation of the Spanish Version of the Chicago Multiscale Depression Inventory and the Study of Factors Associated with Depressive Symptoms;Archives of Clinical Neuropsychology;2022-12-08